Analysts Are Bullish on These Healthcare Stocks: Cassava Sciences (SAVA), Rigel (RIGL)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cassava Sciences (SAVAResearch Report), Rigel (RIGLResearch Report) and Curis (CRISResearch Report) with bullish sentiments.

Cassava Sciences (SAVA)

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Cassava Sciences, with a price target of $124.00. The company’s shares closed last Tuesday at $84.86.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 32.9% and a 37.4% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals, Citius Pharmaceuticals, and Eledon Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cassava Sciences with a $139.75 average price target, which is a 61.1% upside from current levels. In a report issued on July 22, Maxim Group also assigned a Buy rating to the stock with a $190.00 price target.

See today’s analyst top recommended stocks >>

Rigel (RIGL)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rigel, with a price target of $11.00. The company’s shares closed last Tuesday at $3.78.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 25.4% and a 43.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.

Rigel has an analyst consensus of Strong Buy, with a price target consensus of $9.00.

Curis (CRIS)

H.C. Wainwright analyst Edward White maintained a Buy rating on Curis today and set a price target of $20.00. The company’s shares closed last Tuesday at $6.99.

According to TipRanks.com, White is a 5-star analyst with an average return of 27.2% and a 39.7% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Silverback Therapeutics, and Karyopharm Therapeutics.

Currently, the analyst consensus on Curis is a Strong Buy with an average price target of $23.25, which is a 204.3% upside from current levels. In a report released today, B.Riley Financial also reiterated a Buy rating on the stock with a $22.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.